2. Academic Validation
  3. FFA4/GPR120: Pharmacology and Therapeutic Opportunities

FFA4/GPR120: Pharmacology and Therapeutic Opportunities

  • Trends Pharmacol Sci. 2017 Sep;38(9):809-821. doi: 10.1016/j.tips.2017.06.006.
Graeme Milligan 1,  Elisa Alvarez-Curto 2,  Brian D Hudson 2,  Rudi Prihandoko 2,  Andrew B Tobin 3
Affiliations

Affiliations

  • 1 Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK. Electronic address: Graeme.Milligan@glasgow.ac.uk.
  • 2 Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
  • 3 Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK. Electronic address: Andrew.Tobin@glasgow.ac.uk.
PMID: 28734639 DOI: 10.1016/j.tips.2017.06.006
Abstract

Free Fatty Acid Receptor 4 (FFA4), also known as GPR120, is a G-protein-coupled receptor (GPCR) responsive to long-chain fatty acids that is attracting considerable attention as a potential novel therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Although no clinical studies have yet been initiated to assess efficacy in this indication, a significant number of primary publications and patents have highlighted the ability of agonists with potency at FFA4 to improve glucose disposition and enhance Insulin sensitivity in animal models. However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from Cancer to lung function. Here, we discuss and contextualise the basis for these ideas and the results to support these conclusions.

Keywords

G protein-coupled receptor; cancer; diabetes; free fatty acid; lung function inflammation.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-129136
    98.67%, AH-7614 Analog